2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Guidelines for the management of acute coronary syndromes Developed by the task force on …
[HTML][HTML] PCSK9 inhibition: from current advances to evolving future
C Liu, J Chen, H Chen, T Zhang, D He, Q Luo, J Chi… - Cells, 2022 - mdpi.com
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease
synthesized primarily by the liver. It mainly promotes the degradation of low-density …
synthesized primarily by the liver. It mainly promotes the degradation of low-density …
Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
ML O'Donoghue, RP Giugliano, SD Wiviott, D Atar… - Circulation, 2022 - Am Heart Assoc
Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized …
Importance Coronary plaques that are prone to rupture and cause adverse cardiac events
are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins …
are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins …
Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research
P Gaba, BJ Gersh, J Muller, J Narula… - Nature Reviews …, 2023 - nature.com
Understanding the natural history of coronary artery atherosclerosis is necessary to
determine prognosis and prescribe effective therapies. Traditional management of coronary …
determine prognosis and prescribe effective therapies. Traditional management of coronary …
[HTML][HTML] SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non …
Background Sodium–glucose transporter 2 inhibitors (SGLT2-I) could modulate
atherosclerotic plaque progression, via down-regulation of inflammatory burden, and lead to …
atherosclerotic plaque progression, via down-regulation of inflammatory burden, and lead to …
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
E Raschi, M Casula, AFG Cicero, A Corsini… - Pharmacology & …, 2023 - Elsevier
The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …
[HTML][HTML] PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
X Wang, D Wen, Y Chen, L Ma, C You - Cardiovascular diabetology, 2022 - Springer
Abstract Background The Food and Drug Administration has approved Proprotein
Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia …
Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia …
Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: the ARCHITECT study
L Pérez de Isla, JL Díaz-Díaz, MJ Romero… - Circulation, 2023 - Am Heart Assoc
Background: The effect of alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type
9) inhibitor, on coronary plaque burden in patients with familial hypercholesterolemia has …
9) inhibitor, on coronary plaque burden in patients with familial hypercholesterolemia has …
[HTML][HTML] Expanding biology of PCSK9: roles in atherosclerosis and beyond
Abstract Purpose of Review Since the discovery of PCSK9 in 2003, this proprotein
convertase was shown to target specific receptors for degradation in endosomes/lysosomes …
convertase was shown to target specific receptors for degradation in endosomes/lysosomes …